Definitive Contract HHSN261201000081C
Award Date 9/24/10
Potential Completion Date 6/23/11
Potential Value $199K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the Small Business Innovation Research (SBIR) program. The contract was awarded to Kiyatec Inc., a for-profit organization, with a ceiling value of $1,704,285.58. The contract is a definitive contract with a firm fixed price pricing type. The ultimate completion date is November 1, 2019, and the award date was September 30, 2015. The contract was set aside for small businesses. The funding agency is the National Cancer Institute, a civilian agency. The contract...
- <p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
- The National Cancer Institute awarded a Firm Fixed Price Definitive Contract to Vivo Biosciences, Inc. for the "SBIR PHASE I NEW 3D HUBIOGEL CULTURE SYSTEM FOR CANCER STEM CELLS EXPANSION & ANALYSIS" project. The contract has a ceiling value of $219,812.00 and the ultimate completion date is July 21, 2016. This is a Small Business Innovation Research (SBIR) Phase I contract, which supports early-stage research and development of innovative technologies. The contract does not have a...
- This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
- <p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Imaginab, Inc. The contract, valued at $224,264, is for the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract has a firm fixed-price pricing type and a completion date of September 29, 2012.</p>
- This federal contract award, with ID HHSN261201300042C, was issued by the National Cancer Institute, a civilian agency, to Trevigen, Inc., a for-profit manufacturer. The contract is for a Small Business Innovation Research (SBIR) Phase I project on a "Tumor-Aligned Coculture System", with a ceiling value of $252,272. The contract is a definitive, firm-fixed-price contract with a completion date of July 18, 2014. Trevigen, Inc. is the prime contractor, and the award is designated as a...
- This federal contract award from the National Cancer Institute, a civilian agency, was made to Imaginab, Inc., a small business. The contract, valued at $199,363.00, is for a BIOMEDICAL (BASIC) research project under the SBIR Program Phase I Action. The contract is a Definitive Contract with a Firm Fixed Price pricing type, and the ultimate completion date is March 30, 2010. The place of performance is Rancho Park, CA 90064, USA. The contract was set aside for total small business...
- This federal contract award was made by the National Cancer Institute (NCI), a civilian agency, to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business. The $224,452 firm-fixed-price definitive contract was awarded on September 12, 2014, with a period of performance ending on June 30, 2015. The contract was not set aside for any special designation. Based on the information provided, this award appears to be for a standalone contract rather than associated with a larger...
- The National Cancer Institute awarded a $294,719 Firm Fixed Price Definitive Contract to Kiyatec Inc., a small business, for the development of a 3D human tumor co-culture system to accurately predict clinical efficacy. This Small Business Innovation Research (SBIR) Phase I contract was awarded on September 20, 2013, with a completion date of July 21, 2014. The contract was awarded under Topic 314 and aims to create a novel in vitro testing platform to improve the prediction of actual clinical...
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>